

10/552061

JC12 Rec'd PCT/ETC 04 OCT 2005

00005.001277

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
TSUYOSHI MORISHITA, ET AL. ) Examiner: Not Yet Assigned  
Application No.: Not Yet Assigned ) Group Art Unit: Not Yet Assigned  
(National Phase of PCT Application No. )  
PCT/JP2004/005503 filed April 16, 2004) )  
Filed: Concurrently herewith )  
For: NERVE REGENERATING DRUG ) October 3, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

References A-I are cited in Applicants' International Search Report, of record. Additionally, reference K is discussed at specification page 5, lines 8-13. A concise explanation of its relevance may be found therein.


10/552061  
JC12 Rec'd PCT/US 04 OCT 2005

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3800  
Facsimile: (212) 218-2200

LSP\ac

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			ATTY DOCKET NO. 00005.001277		APPLICATION NO. 10/552061 Not Yet Assigned			
			APPLICANT <b>TSUYOSHI MORISHITA, ET AL.</b>					
			FILING DATE <b>Concurrently herewith</b>		GROUP <b>Not Yet Assigned</b>			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	<b>5,883,114</b>	<b>3/99</b>	<b>Kleinschroth, et al.</b>		<b>514</b>	<b>410</b>	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
	B	<b>1 057 484</b>	<b>12/00</b>	<b>EP</b>				
	C	<b>WO 00/38675</b>	<b>7/00</b>	<b>PCT</b>				
	D	<b>1 224 932</b>	<b>7/02</b>	<b>EP</b>				
	E	<b>WO 02/062387</b>	<b>8/02</b>	<b>PCT</b>				
	F	<b>0 397 060</b>	<b>11/90</b>	<b>EP</b>				<b>No</b>
	G	<b>WO 01/37819</b>	<b>5/01</b>	<b>PCT</b>				<b>Abstract</b>
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)								
	H	<b>Leost, et al., "Paullones are potent inhibitors of glycogen synthase kinase-3<math>\beta</math> and...", Eur. J. Biochem., Vol. 267 (2002), pages 5983-5994</b>						
	I	<b>Chen, et al., "Enhancement of Hippocampal Neurogenesis by Lithium", Journal of Neurochemistry, Vol. 75, No. 4 (2000), pages 1729-1734</b>						
	J	<b>García-Pérez, et al., "Lithium Induces Morphological Differentiation of Mouse...", Journal of Neuroscience Research, Vol. 57, (1999), pages 261-270</b>						
	K	<b>Eldar-Finkelman, "Glycogen synthase kinase 3:an emerging therapeutic target", TRENDS in Molecular Medicine, Vol. 8, No. 3 (2002), pages 126-132</b>						
EXAMINER				DATE CONSIDERED				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.